云顶新耀-B早盘股价持续上扬现涨超8%

新浪港股2023-09-22

云顶新耀-B（01952）早盘股价持续上扬，大涨8.49%，现报19.68港元，成交额4266.546万港元。　　云顶新耀发布公告，与Kezar订立合作及授权许可协议。据此，Kezar授予公司独家授权许可，在大中华区、韩国及若干东南亚国家开发、生产及商业化Kezar的主要候选药物zetomipzomib，其为一种用于治疗包括狼疮性肾炎在内的一系列自身免疫性疾病的新同类首创选择性免疫蛋白酶体抑制剂...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2369585384?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-09-22 10:23","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2369585384","market":"hk","top_or_hot":-1,"title":"云顶新耀-B早盘股价持续上扬 现涨超8%","media":"新浪港股","content":"<div>\n<p>云顶新耀-B（01952）早盘股价持续上扬，大涨8.49%，现报19.68港元，成交额4266.546万港元。\n　　云顶新耀发布公告，与Kezar订立合作及授权许可协议。据此，Kezar授予公司独家授权许可，在大中华区、韩国及若干东南亚国家开发、生产及商业化Kezar的主要候选药物zetomipzomib，其为一种用于治疗包括狼疮性肾炎在内的一系列自身免疫性疾病的新同类首创选择性免疫蛋白酶体抑制剂...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-22/doc-imznpwaq8122176.shtml\">网页链接</a>\n\n</div>\n","source":"highlight_sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>云顶新耀-B早盘股价持续上扬 现涨超8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n云顶新耀-B早盘股价持续上扬 现涨超8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-22 10:23 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-22/doc-imznpwaq8122176.shtml><strong>新浪港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>云顶新耀-B（01952）早盘股价持续上扬，大涨8.49%，现报19.68港元，成交额4266.546万港元。\n　　云顶新耀发布公告，与Kezar订立合作及授权许可协议。据此，Kezar授予公司独家授权许可，在大中华区、韩国及若干东南亚国家开发、生产及商业化Kezar的主要候选药物zetomipzomib，其为一种用于治疗包括狼疮性肾炎在内的一系列自身免疫性疾病的新同类首创选择性免疫蛋白酶体抑制剂...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-22/doc-imznpwaq8122176.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-22/doc-imznpwaq8122176.shtml","article_id":"2369585384","we_media_id":null,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-22/doc-imznpwaq8122176.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2369585384","pubTimestamp":1695349387,"columns":[],"sourceInfo":{"source_id":"highlight_sina","name":"新浪港股"},"weMediaInfo":null,"summary":"云顶新耀-B（01952）早盘股价持续上扬，大涨8.49%，现报19.68港元，成交额4266.546万港元。\n　　云顶新耀发布公告，与Kezar订立合作及授权许可协议。据此，Kezar授予公司独家授权许可，在大中华区、韩国及若干东南亚国家开发、生产及商业化Kezar的主要候选药物zetomipzomib，其为一种用于治疗包括狼疮性肾炎在内的一系列自身免疫性疾病的新同类首创选择性免疫蛋白酶体抑制剂。\n\n现在送您60元福利红包，直接提现不套路~~~快来参与活动吧！\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1583":"高瓴概念","01952":"云顶新耀","BK1574":"生物医药B类股"},"translate_title":"Genting Xinyao-B's share price continued to rise in early trading and is now up more than 8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"云顶新耀-B（01952）早盘股价持续上扬，大涨8.49%，现报19.68港元，成交额4266.546万港元。\n　　云顶新耀发布公告，与Kezar订立合作及授权许可协议。据此，Kezar授予公司独家授权许可，在大中华区、韩国及若干东南亚国家开发、生产及商业化Kezar的主要候选药物zetomipzomib，其为一种用于治疗包括狼疮性肾炎在内的一系列自身免疫性疾病的新同类首创选择性免疫蛋白酶体抑制剂。\n\n现在送您60元福利红包，直接提现不套路~~~快来参与活动吧！\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2369585384","isCrawlerRequest":true}

云顶新耀-B早盘股价持续上扬 现涨超8%

精彩评论

云顶新耀-B早盘股价持续上扬现涨超8%